Navigation Links
Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
Date:12/2/2010

SCHAUMBURG, Ill., Dec. 2, 2010 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA's approval of four presentations of midazolam injection, USP, a general anesthetic.  Sagent expects to launch midazolam, which will be offered in latex-free vials, in 2011.  According to 2010 IMS data, the annual U.S. market for injectable midazolam approximated $52 million.  

"Approval of midazolam marks the ninth FDA approval from our collaboration with Strides Arcolab and is an important addition to our anesthesiology portfolio," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent.  "Each of our anesthesiology products, as well as all of our injectable products, includes Sagent's proprietary PreventIV Measures packaging and labeling designed to help with the reduction of medication errors."

Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 20 injectable products for the U.S. market.  Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the United States.

About Midazolam Injection, USP

Midazolam is indicated for preoperative use (sedation, anxiolysis, amnesia), prior to or during diagnostic, therapeutic or endoscopic procedures, intravenously for induction of general anesthesia, and for continuous intravenous infusion for sedation of intubated and mechanically ventilated patients.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, boxed warnings and prescribing information.

About PreventIV Measures™

PreventIV Measures™ is Sagent's comprehensive, user-driven and patient-centered approach to product labeling and packaging that is designed to help prevent medication errors. It incorporates unique label and carton designs, cap and label colors, bar coding and other features that are designed to make it easier to differentiate drugs and identify the correct dose.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.  

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.

About Strides Arcolab, Ltd.

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across six countries, including its joint venture with Aspen in India and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
5. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
6. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
7. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
8. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
9. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
10. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
11. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , December 7, 2016 ... Market Research titled , Global Market Study on Multiplex Detection ... 2024 , the global multiplex detection immunoassay market is expected ... period 2016-2024. ... , , ...
(Date:12/7/2016)... FRANCISCO , December 7, 2016 ... expected to reach a value of USD 3.9 ... by Grand View Research, Inc. The growth of ... of donor and continuous technological advancements by the ... increasing continuously due to increasing donation, rising awareness ...
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC announced ... recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 and ... same target on B cells as Rituxan and maintains ... but is also involved in tumor targeting, engagement of ... effect. The results of the study (abstract #95954) were ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward ... comments on social media that offer a rare glimpse into the mind of those ... and New York Times bestselling author, has described people with ADHD as having “Ferrari ...
(Date:12/7/2016)... Hollywood, Fl (PRWEB) , ... December 07, 2016 , ... When it came time to ... new heart. Just 40 minutes later, the Pediatric Heart Transplant team at Joe ... true making the Weston teen the hospital’s 30th heart transplant recipient. , “He was ...
(Date:12/7/2016)... ... 07, 2016 , ... Baciocco Brothers Insurance Agency, a northern ... Sacramento/Folsom region, is initiating a charity event to raise support and awareness for ... treatment center in Sacramento works to provide area teens and families with treatment ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving ... are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... to the children of the world. , In exchange for generous donations, customers will ...
(Date:12/7/2016)... ... 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, The ... of America, declared on her radio program in November 2016 the need to educate ... bullies attack leaders in corporate America, they are trying to take advantage of successful ...
Breaking Medicine News(10 mins):